In vivo effects of Leflunomide on normal pancreatic islet and syngeneic islet graft function

Transplantation

Volumn 63, Issue 5, 1997, Pages 716-721

  Guo, Zhiguang ^a   Chong, Anita S F ^a   Shen, Jikun ^a   Foster, Preston ^a   Sankary, Howard N ^a   McChesney, Lawrence ^a   Mital, Deepak ^a   Jensik, Stephen C ^a   Gebel, Howard ^a   Williams, James W ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; GLUCOSE; LEFLUNOMIDE; STREPTOZOCIN; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETOGENESIS; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GRAFT REJECTION; HYPERGLYCEMIA; MALE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; RAT;

ANIMALS; BODY WEIGHT; CYCLOSPORINE; IMMUNOSUPPRESSIVE AGENTS; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; ISOXAZOLES; RATS; TACROLIMUS; TIME FACTORS;

EID: 0030999182     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199703150-00018     Document Type: Article

References (25)

1. Jindal RM. Posttansplant diabetes mellitus - a review. Transplantation 1994; 58: 1289.
2. Ingle DJ. The production of glucosuria in the normal rat by means of 17-hydroxy-11-dehydrocorticosterone, Endocrinology 1941; 29: 649.
3. Venkatesan N, Davidson MB, Hutchinson A. Possible role for the glucose-fatty acid cycle in dexamethasone-induce insulin antagonism in rats. Metabolism 1987; 36: 883.
4. Starzl TE. Experience in renal transplantation. Philadelphia: Saunders, 1964.
5. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. J Clin Endocrinol Metab 1982; 54: 131.
6. Ishizuka J, Gugliuzza KK, Wassmuth Z, et al. Effects of FK 506 and cyclosporine on dynamic insulin secretion from isolated dog pancreatic islets. Transplantation 1993; 56: 1486.
7. Hahn HJ, Laube F, Lucke S, et al. Toxic effects of cyclosporine on the endocrine pancreas of Wistar rats. Transplantation 1986; 41: 44.
8. Hirano Y, Fujihira S, Ohara K, Katsuki S, Noguchi H. Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 1992; 53: 889.
9. Tze WJ, Tai T, Murase N, Tzakis A, Starzl TE. Effect of FK506 on glucose metabolism and insulin secretion in normal rats. Transplant Proc 1991; 23: 3158.
10. Guo Z, Chong ASF, Shen J, et al. Prolongation of rat islet allograft survival by the immunosuppressive agent leflunomide. Transplantation 1997; 63: 711.
11. Williams JW, Xiao F, Foster P, et al. Leflumomide in experimental transplantation: control of rejection and alloantibody production, reversal of acute rejection, and interaction with cyclosporine. Transplantation 1994; 57: 1223.
12. Kuchle CC, Thoenes GH, Langer KH, Schorlemmer H-U, Barrlett RR, Schleyerbach R. Prevention of kidney and skin graft rejection in rats by leflunomide, a new immunosuppressive isoxazole derivative. Transplant Proc 1991; 23: 1083.
13. D'sliva M, Candinas D, Achilleos O, et al. The immunomodulatory effect of leflunomide in rat cardiac allotransplantation. Transplantation 1995; 60: 430.
14. MeChesney LP, Xiao F, Sankary HN, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994; 57: 1717.
15. Morris RE, Huang X, Cao W, Zheng B, Shorthouse RA. Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening after balloon catheter injury. Transplant Proc 1995; 27: 445.
16. Xiao F, Chong A, Foster P, et al. Leflunomide on acute rejection in hamster to rat cardiac xenografts. Transplantation 1995; 58: 828.
17. Boudreaux JP, McHugh L, Canafax DM, et al. The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 1987; 44: 376.
18. Mejia G, Arbelaez M, Henao JE, Arango JL, Garcia A. Cyclosporine-associated diabetes mellitus in renal transplants. Clin Transplant 1989; 3: 260.
19. Ueki M, Yasunami Y, Ryu S, et al. Functional and morphologic characterization of renal subcapsular islet isografts in rats treated with FK506. Transplant Proc 1994; 26: 740.
20. Ricordi C, Zeng Y Alejandro R, et al. In vivo effect of FK 506 on human pancreatic islets. Transplantation 1991; 52: 519.
21. Kaufman DB, Morel P, Jane Field M, Munn SP, Sutherland DER. Purified canine islet autografts: functional outcome as influenced by islet number and implantation site. Transplantation 1990; 50: 385.
22. Hiller WFA, Klempnauer J, Luck R, Steiniger B. Progressive deterioration of endocrine function after intraportal but not kidney subcapsular rat islet transplantation. Diabetes 1991; 40: 134.
23. Van Suylichem PTR, Strubbe JH, Houwing H, Wolters GHJ, Van Schilfgaarde R. Rat islet isograft function: effect of graft volume and transplantation site. Transplantation 1994; 57: 1010.
24. Hahn HJ, Dunger A, Laube F, et al. Reversibility of the acute toxic effect of cyclosporine A on pancreatic B cells of Wistar rats. Diabetologia 1986; 29: 489.
25. Sandberg J-O, Andersson A. Toxicity in vivo of different immunosuppressive drugs in fetal porcine pancreatic islets. Transplantation 1996; 61: 1211.